Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024
September 25, 2024 09:00 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an abstract...
UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
September 24, 2024 01:00 ET
|
Biogen Inc.
Phase 3 PHOENYCS GO study met the primary endpoint demonstrating clinical improvement in moderate-to-severe systemic lupus erythematosus; Clinical improvements were observed among key secondary...
Allsup Supports “2024 Walk To End Lupus Now” on Sept. 7
August 22, 2024 08:22 ET
|
Allsup
Belleville, Illinois, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Allsup, the nation’s premier disability representation company®, is proud to be a silver sponsor of the “2024 Walk To End Lupus Now, St....
Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements
August 13, 2024 16:05 ET
|
Alumis Inc.
– Initiated patient dosing in ESK-001 Phase 3 ONWARD clinical program in moderate-to-severe plaque psoriasis – – Initiated Phase 1 clinical trial for A-005 in healthy participants – – Completed IPO...
Exagen to Announce Second Quarter 2024 Results on August 5, 2024
July 22, 2024 09:00 ET
|
Exagen Inc.
CARLSBAD, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended June 30, 2024, before...
Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering
July 18, 2024 19:08 ET
|
Artiva Biotherapeutics Inc.
Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering
Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board
July 09, 2024 08:00 ET
|
Caribou Biosciences, Inc.
-- Dr. Laufer is an immunologist advancing the scientific understanding and treatment of autoimmune diseases -- BERKELEY, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences,...
Exagen Announces Campaign for Lupus Awareness Month
May 06, 2024 16:05 ET
|
Exagen Inc.
CARLSBAD, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch...
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
April 04, 2024 16:00 ET
|
Caribou Biosciences, Inc.
-- FDA has cleared Caribou’s IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- Driven by encouraging initial...
Alumis Presents Positive Data from Phase 2 Clinical Trial of ESK-001, an Oral Allosteric TYK2 Inhibitor for the Treatment of Plaque Psoriasis, at AAD Annual Meeting
March 09, 2024 12:00 ET
|
Alumis Inc
Alumis today announced the presentation of positive clinical data from a Phase 2 clinical trial of ESK-001 at AAD 2024.